Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The ipriflavone story]

L György1, N Mihály, E P Marian

  • 1Chinoin Gyógyszer-és Vegyészeti Termékek Gyára Rt., Budapest.

Acta Pharmaceutica Hungarica
|November 1, 1995
PubMed
Summary

Ipriflavone, initially a veterinary fodder additive, was later recognized for its antianginal effects. It became an effective osteoporosis treatment launched in Japan in 1988.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Lege artis medicinae : uj magyar orvosi hirmondo·2001
Same author

Consumption of antihistamines and antiasthmatics in Hungary during 1992-1996.

International archives of allergy and immunology·1999
Same author

[The use of Hungarian medical terminology].

Orvosi hetilap·1996
Same author

[Successful surgical management of cardiovascular thrombosis and aortic coarctation, caused by protein C deficiency, in a newborn infant].

Orvosi hetilap·1996
Same author

[Synthesis of isoflavones].

Acta pharmaceutica Hungarica·1995
Same author

[Forced stability study of ipriflavone].

Acta pharmaceutica Hungarica·1995

Area of Science:

  • Pharmacology
  • Drug Development
  • Medicinal Chemistry

Context:

  • Ipriflavone's development involved a complex journey from veterinary use to human therapeutics.
  • Its antianginal effects were identified, leading to further investigation.

Purpose:

  • To detail the historical development and therapeutic transition of ipriflavone.
  • To highlight the discovery of ipriflavone's efficacy in treating osteoporosis.

Summary:

  • Ipriflavone, an original molecule, initially served as a fodder additive in veterinary medicine.
  • Following the discovery of its antianginal properties, ipriflavone underwent development for human use.
  • It was registered and launched as an osteoporosis treatment in Japan in 1988, 19 years after its synthesis was developed.

Impact:

  • The successful repurposing of ipriflavone demonstrates the potential for discovering new therapeutic applications for existing molecules.
  • This case highlights the lengthy and often challenging path of drug development and market introduction.

Related Experiment Videos